1. Home
  2. HPK vs PCRX Comparison

HPK vs PCRX Comparison

Compare HPK & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HighPeak Energy Inc.

HPK

HighPeak Energy Inc.

HOLD

Current Price

$7.45

Market Cap

866.8M

Sector

Energy

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$23.05

Market Cap

999.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HPK
PCRX
Founded
2019
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
866.8M
999.0M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
HPK
PCRX
Price
$7.45
$23.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$12.00
$30.25
AVG Volume (30 Days)
471.9K
655.2K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
2.30%
N/A
EPS Growth
N/A
107.44
EPS
N/A
0.19
Revenue
$863,359,000.00
$541,533,000.00
Revenue This Year
N/A
$6.78
Revenue Next Year
N/A
$8.54
P/E Ratio
N/A
$124.74
Revenue Growth
N/A
26.04
52 Week Low
$3.85
$18.80
52 Week High
$9.13
$27.66

Technical Indicators

Market Signals
Indicator
HPK
PCRX
Relative Strength Index (RSI) 52.22 34.82
Support Level $7.23 $22.03
Resistance Level $8.32 $24.34
Average True Range (ATR) 0.55 1.09
MACD 0.06 -0.43
Stochastic Oscillator 39.01 0.22

Price Performance

Historical Comparison
HPK
PCRX

About HPK HighPeak Energy Inc.

HighPeak Energy Inc is an independent crude oil and natural gas exploration and production company that explores for, develops and produces crude oil, NGL, and natural gas prominently in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S. The majority of the company's revenue is derived from the Crude oil sales.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: